🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06120426
Recruiting Observational

En Bloc Resection Versus Separation Surgery Combined With Radiotherapy for the Treatment of Spinal Oligometastatic Tumor.

NCT06120426 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai Changzheng Hospital
Phase
Observational
Started
2023-07-01
Last updated
2023-11-13

Condition(s) studied

Spinal MetastasesSpinal TumorRadiotherapyMalignant Bone TumorSurgery

Investigational drug(s) / intervention(s)

total en bloc spondylectomy

total en bloc spondylectomy: Total enbloc resection (TES) is one of the most challenging surgeries in spinal surgery and a classic surgical method. It not only relieve spinal cord compression and delays tumor recurrence, but also prolongs patient survival, significantly reduces hand surgery trauma, and improves surgical safety. However, for cases with extensive tumor invasion, methods such as separation surgery should be used to relieve spinal cord nerve compression, rebuild spinal stability, and provide conditions for postoperative radiotherapy.

Study summary

The purpose of this clinical trial is to explore the impact of En bloc surgery and separation surgery combined with radiation therapy on the prognosis and survival of patients with spinal oligometastatic cancer, describe the clinical results, and optimize future treatment goals

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: * 1\) Be able to sign written informed consent. * 2\) Age range from 18 to 75 years old, regardless of gender. * 3\) Within conservative treatment, the patient still has uncontrollable pain, metastatic cancer lesions that still progress, spinal instability/potential instability, or symptoms of spinal cord/nerve compression. * 4\) After the patient underwent Positron Emission Tomography-Computed Tomography (PET-CT) examination, it was indicated that there were no more than 3 metastatic organs and no more than 5 metastatic lesions in the whole body of cancer. Among them, there was at least 1 spinal metastasis and at most 5 spinal metastases. * 5\) Imaging examinations (enhanced MRI, enhanced CT, X-ray) indicate the presence of spinal metastasis. * 6\) The expected survival period is ≥ 6 months. * 7)No other surgical contraindications Exclusion Criteria: * 1\) Primary tumors of the spine or multiple tumors of the body, with\>3 metastatic organs and\>5 metastatic sites. * 2\) Previously underwent spinal surgery, or received radiotherapy for the responsible segment of this treatment. * 3\) Severe heart, lung, liver, kidney or other diseases affecting the surgery. * 4\) Having cognitive impairment, sensory aphasia, and inability to understand basic instructions. * 5\) Participated in clinical trials of other drugs or medical devices within 3 months prior to enrollment. * 6\) Infectious diseases. * 7\) Refuse to follow up or participate. * 8\) The researchers determine that the patients are not suitable for enrollment this clinical trail.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Shanghai Changzheng hospital Shanghai Shanghai Municipality Recruiting

More Shanghai Changzheng Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06120426 on ClinicalTrials.gov ↗ ← All trials in China